Ligand Pharma share price logo

Ligand Pharma

NASDAQ: LGND

Mid Cap

$318.26

-0.52

(-0.16%)

as on

Ligand Pharma Stock Performance

as on October 30, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $309.63
    $323.62
    downward going graph

    2.71%

    Downside

    1.68%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $175.89
    $326.63
    downward going graph

    44.73%

    Downside

    2.63%

    Upside

    downward going graph

Ligand Pharma share price movements today

Previous Close
$318.78
Open
$315.93
Volume
256.6K
Market Cap
$6.2B
Day's Low - High
$309.63 - $323.62
52 Week Low - High
$175.89 - $326.63

Ligand Pharma Historical Returns

1 Month Return
+ 2.71 %
3 Month Return
+ 10.68 %
1 Year Return
+ 72.76 %
3 Year Return
+ 543.09 %
5 Year Return
+ 118.43 %

Ligand Pharma Stock Fundamentals & Key Indicators

Check Ligand Pharma market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$6.2B

EPS (TTM)

10.01

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

8.25%

PE Ratio (TTM)

31.14

Industry PE ratio

-8.59

PEG Ratio

0.03

EBITDA

274.0M

Revenue (TTM)

290.5M

Profit Margin

98.58%

Return On Equity TTM

20.06%

Ligand Pharma vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Ligand Pharma with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Ligand Pharma image
Ligand Pharma
StrongBuy$6.2B118.43%31.1498.58%0.00%
Moderna image
Moderna
Neutral$83.0B-37.96%-26.06-12.57%0.00%
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
StrongBuy$132.1B186.43%30.0886.04%0.00%
Regeneron image
Regeneron
Buy$84.0B27.09%19.4984.86%0.45%

Stock Returns calculator for Ligand Pharma Stock including INR - Dollar returns

The Ligand Pharma stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Ligand Pharma investment value today

Current value as on today

₹1,85,829

Returns

₹85,829

(+85.83%)

Returns from Ligand Pharma Stock

₹72,480 (+72.48%)

Dollar Impact

₹13,349 (+13.35%)

Analyst Recommendation on Ligand Pharma Stock

Based on 8 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 8 analysts, 100% of analysts recommend a 'BUY' rating for Ligand Pharma. Average target price of $345.75

Ligand Pharma Share Price Target

Get share price movements and forecasts by analysts on Ligand Pharma.

What analysts predicted

7.95%UPSIDE

Target Price

$345.75

Current Price

$318.26

Analyzed by

8 Analysts

High

$406

Target

$345.75

Low

$326

Ligand Pharma target price $345.75, a slight upside of 7.95% compared to current price of $318.26. According to 8 analysts rating.

Indian Investors' Interest in Ligand Pharma Stock

Search interest for Ligand Pharma Stock has decreased by -6% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-6% versus previous 30 day period

Ligand Pharma Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
30
41
51
42
45
47
115
59
51
63
Gross Profit
19
56
39
39
40
44
90
85
49
60
Operating Income
2
-19
3
-9
-36
8
54
20
17
8
EBITDA
122
-55
3
-29
-40
20
149
66
-14
72
Interest Expense
0
1
0
0
0
1
0
1
1
1
Depreciation
8
8
8
8
8
8
8
9
8
8
Income Before Tax
113
-65
-6
-39
-50
11
141
56
-24
64
Income Tax Expense
27
-13
0
-8
-7
6
23
11
-10
15
Net Income
86
-51
-7
-31
-42
4
117
44
-13
48
Net Profit Margin
64.27%
136.90%
75.88%
93.37%
89.30%
93.90%
78.50%
143.56%
95.99%
94.95%

Ligand Pharma Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
141
251
120
163
241
196
131
167
268
Gross Profit
135
245
108
133
179
143
96
156
261
Operating Income
68
163
807
37
103
3
11
-22
47
EBITDA
80
236
876
56
142
81
100
40
192
Interest Expense
11
48
35
27
19
1
0
3
4
Depreciation
11
14
43
27
50
43
36
35
33
Income Before Tax
57
173
796
1
72
36
63
2
158
Income Tax Expense
44
30
167
-5
-4
41
9
6
34
Net Income
12
143
629
-2
57
-33
52
-4
124
Net Profit Margin
96.20%
97.48%
90.57%
81.40%
74.26%
73.08%
73.31%
93.37%
97.54%

Ligand Pharma Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
86
-51
-7
-31
-42
4
117
44
-13
48
Operating Cash Flow
18
13
36
28
-25
15
13
45
48
24
Investing Cash Flow
-3
-54
-46
-38
4
-10
-353
-18
-94
321
Financing Cash Flow
12
9
55
20
-4
14
409
8
-14
546
Change in Cash
27
-31
45
8
-24
19
71
35
-59
891

Ligand Pharma Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
12
143
629
-2
57
-33
52
-4
124
Operating Cash Flow
93
194
-29
54
78
137
49
97
49
Investing Cash Flow
-84
-423
466
231
30
163
-11
-143
-377
Financing Cash Flow
-7
328
-485
-310
-137
-275
-59
97
428
Change in Cash
1
99
-47
-24
-28
25
-22
49
102

Global Institutional Holdings in Ligand Pharma

Check out the Institutions with significant holdings in Ligand Pharma.

Funds
Holdings
iShares
11.64%
Vanguard
9.22%
Delaware Group Equity Funds V
8.08%
VANGUARD INDEX FUNDS
7.62%
JANUS INVESTMENT FUND
3.89%
See all

Ligand Pharma News & Key Events

  • img

    Today's Timeline - 29 October

    Thu, 05:06 PM

    -

    Ligand raises FY26 adjusted EPS view to $9.50-$9.75 and backs revenue view of $270M-$310M.

Insights on Ligand Pharma

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 51.72M → 63.69M (in $), with an average increase of 18.8% per quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -13.34M → 48.50M (in $), with an average increase of 127.5% per quarter

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, LGND has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 6 months, LGND stock has moved up by 41.8%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 767.1% return, outperforming this stock by 694.3%

About Ligand Pharma

Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
OrganisationLigand Pharma
Headquarters555 Heritage Drive, Jupiter, FL, 33458, US
IndustryBiotechnology
CEOTodd C. Davis

Key Management of Ligand Pharma

Name

Title

Dr. Keith Marschke Ph.D.

Senior Vice President of Biology & Scientific Affairs

Dr. Vincent D. Antle Ph.D.

Senior Vice President of Technical Operations & QA - Capitsol

Dr. Karen R. Reeves M.D.

Senior VP of Investments & Head of Clinical Strategy

Mr. Richard B. Baxter

Senior VP of Investment Operations

Mr. Andrew T. Reardon J.D.

Chief Legal Officer & Secretary

Mr. Paul J. Hadden

Senior Vice President of Investments & Business Development

Ms. Melanie J. Herman CPA

Executive Director of Investor Relations and Financial Planning & Analysis

Mr. Todd C. Davis Ph.D.

CEO & Director

Mr. Octavio Espinoza

Chief Financial Officer

Ms. Marjorie Fackovec

Head of People Operations

FAQs

What is Ligand Pharma share price today?

Ligand Pharma share price today is $318.26 as on at the close of the market. Ligand Pharma share today touched a day high of $323.62 and a low of $309.63.

What is the 52 week high and 52 week low for Ligand Pharma share?

Ligand Pharma share touched a 52 week high of $326.63 on and a 52 week low of $175.89 on . Ligand Pharma stock price today i.e. is closed at $318.26,which is 2.56% down from its 52 week high and 80.94% up from its 52 week low.

What is Ligand Pharma's market capitalisation today?

Ligand Pharma market capitalisation is $0.01T as on .

How to invest in Ligand Pharma Stock (LGND) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Ligand Pharma on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Ligand Pharma Stock (LGND) from India?

Indian investors can start investing in Ligand Pharma (LGND) shares with as little as ₹95.25 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹952.50 in Ligand Pharma stock (as per the Rupee-Dollar exchange rate as on ). Based on Ligand Pharma share’s latest price of $318.26 as on October 30, 2026 at 1:29 am IST, you will get 0.0314 shares of Ligand Pharma. Learn more about fractional shares .

What are the returns that Ligand Pharma has given to Indian investors in the last 5 years?

Ligand Pharma stock has given 118.43% share price returns and 27.03% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?